Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
South Korea needs political reform to attract investor interest: David Roche
06:15am, Friday, 04'th Apr 2025
David Roche, strategist at Quantum Strategy, and Victor Cha, president of the CSIS geopolitics and foreign policy department, discuss the possibility of constitutional reform in South Korea.
Roche: Consumers Aren't "Strong Enough" to Bear Tariffs
03:40pm, Thursday, 03'rd Apr 2025
Cullen Roche says that markets are losing sight of the fact that things were “already dicey” economically even before tariffs. He calls the next 12-18 months “pretty worrisome.
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
03:23pm, Thursday, 03'rd Apr 2025
In March, Sarepta Therapeutics, Inc. SRPT shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study
11:50am, Thursday, 03'rd Apr 2025
RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.
Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer's at AD/PD 2025
09:30am, Thursday, 03'rd Apr 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data were presented at the AD/PD 2025 International Conferen
Roche presents novel therapeutic and diagnostic advancements in Alzheimer's at AD/PD 2025
09:30am, Thursday, 03'rd Apr 2025
Basel, 3 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data were presented at the AD/PD 2025 International Conference on Alzheimer's and Parkinson's Diseases in Vienna, Aust
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
03:12pm, Wednesday, 02'nd Apr 2025
Roche Holdings AG RHHBY on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion in adult patients with relapsing multiple sclerosis (RM
Roche fails in bid to increase dose of MS drug Ocrevus
11:48am, Wednesday, 02'nd Apr 2025
Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy benefit over the standard dose, a setback in a bid to further boost usage of t
Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis
11:45am, Wednesday, 02'nd Apr 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (
Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis
11:45am, Wednesday, 02'nd Apr 2025
Basel, 02 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently a
Quest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer Screening
07:06am, Wednesday, 02'nd Apr 2025
Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to scree
Roche Annual General Meeting 2025
08:30am, Tuesday, 25'th Mar 2025
Basel, 25 March 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders had approved all proposals of the Board of Directors at its Annual General Meeting. The 616 shareholde
The Zacks Analyst Blog Roche Holding, Comcast, Eaton Corp and National Presto Industries
04:20am, Tuesday, 25'th Mar 2025
Roche Holding, Comcast, Eaton Corp and National Presto Industries are included in this Analyst Blog.
Roche abandons global diversity targets on concern over U.S. executive orders
06:45am, Wednesday, 19'th Mar 2025
Swiss drugmaker Roche has abandoned global targets for a more diverse workforce to avoid penalties from recent U.S. executive orders, the latest in a slew of companies to do so.
Oxford, UK and San Jose, California, 19th March 2025 – Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based
